The acquisition will include a product portfolio that features AQUI-S – a sedative for use during treatment, pumping, transportation and handling of salmon and rainbow trout – and Finquel, a widely-used anaesthetic mainly used during vaccination and handling events such as lice counting.
“The Scan Aqua AS acquisition reinforces MSD Animal Health’s commitment to investing in fish health and fish welfare, as well as to offering its customers new solutions. Vaccination is a key pillar of our preventative health solutions and the use of sedatives complements this approach,” says Dafydd Morris, general manager of MSD Animal Health Norway.
“We are delighted to work with MSD Animal Health. They are the ideal partner to help realize the full potential of our fish health products in Norway and in other markets,” says Ole Kristian Kaurstad, CEO of Scanvacc.